Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P645 - ESOC25-1785 INTRAVENOUS THROMBOLYSIS BEFORE ENDOVASCULAR TREATMENT IN ACUTE VERTEBROBASILAR OCCLUSIONS: A POOLED ANALYSIS OF THE FRENCH AND GERMAN NATIONAL STROKE REGISTRIES Raoul Pop 1 , Stefanos Finitsis 2 , Bertrand Lapergue 3 , Marek Sykora 4 , Daniel Strbian *5 , Joshua Mbroh 6 , Xinchen Hui 6 , Florian Hennersdorf 7 , Ulrike Ernemann 7 , Sven Poli 6 , Benjamin Gory 8 1 University Hospitals Strasbourg, Strasbourg, France, 2 4Ahepa Hospital, Aristotle University of Thessaloniki, Greece, Thessaloniki, Greece, 3 Department of Neurology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France, Paris, France, 4 6Department of Neurology, St
FDA's evaluation concluded that the criteria weighed against placement on the list, citing inadequate physicochemical characterization, immunogenicity concerns from impurities and aggregates, lack of clinical effectiveness data for any approved use, and absence of published human exposure data for the proposed subcutaneous and topical routes
Its legal status varies by jurisdiction, and athletes should note that peptides are scrutinized by anti-doping authorities BPC-157 is not a permitted substance in regulated competition
Unlike larger proteins, peptides are small enough to enter circulation and interact with cells rapidly and precisely
It should be noted that there are specific anabolic steroids that are exempt from Schedule III
The emerging science might not be the problem, but these peptides should be clearly labeled regarding the risks they pose
